Welcome to our dedicated page for Elixxer news (Ticker: ELIXF), a resource for investors and traders seeking the latest updates and insights on Elixxer stock.
Elixxer Ltd (ELIXF) news coverage provides updates on this Canadian micro-cap company's corporate developments, financial restructuring activities, and governance changes. As a smaller publicly traded company, Elixxer's news flow primarily centers on shareholder communications, debt management initiatives, and regulatory matters.
News for micro-cap companies like Elixxer often differs from large-cap coverage. Rather than quarterly earnings calls and analyst commentary, expect updates on corporate actions such as debt settlements, director appointments, shareholder meeting results, and regulatory filings. These announcements provide insight into management's efforts to strengthen the company's financial foundation and corporate governance.
Following Elixxer news helps investors track the company's progress on restructuring initiatives and any changes to its business strategy. Corporate press releases and shareholder notices offer the most direct view into company developments, given the limited analyst coverage typical for OTC-traded micro-cap stocks.
Bookmark this page to receive timely updates on Elixxer Ltd announcements, corporate filings, and material developments as they become available.
Elixxer (OTC:ELIXF) reported results of its annual and special shareholders meeting held on December 30, 2025. A total of 3,798,208 shares were voted, representing 33.50% of issued common shares.
Shareholders approved election of four directors with ~98.99% support, appointment of CAN Partners LLP as auditors (99.06% in favour), a name-change special resolution, a share consolidation of up to 90-for-1, re-approval of the stock option plan, authorization to issue shares to settle indebtedness, and voluntary delisting from TSXV.
Elixxer (OTC:ELIXF) called its annual and special meeting for December 30, 2025 to seek shareholder approvals including appointment of auditors, director elections, a proposed name change, stock option plan, a $6,923,742.46 Debt Settlement, voluntary TSXV de‑listing and re‑listing, and up to a 100:1 share consolidation.
The company corrects prior releases: no Common Shares have been issued under the Debt Settlement because minority shareholder approval is required under MI 61‑101 and TSXV Policy 4.4. The Debt Settlement would issue up to 83,924,151 shares at $0.0825, including 79,075,667 shares to insiders and $6,323,742.46 owed to AIP.
Elixxer Ltd. (TSXV: ELXR.H) has completed a significant debt settlement transaction, converting $5.53 million of debt into 67,014,183 common shares at $0.0825 per share. The transaction includes both arm's length and non-arm's length creditors, with an insider receiving 62,165,699 shares.
Following the settlement, AIP Convertible Private Debt Fund L.P. has significantly increased its ownership position from 32.04% to 83.98% of outstanding shares on an undiluted basis. The transaction was approved by independent board members and is subject to TSX Venture Exchange final acceptance, with issued shares having a four-month hold period.
Elixxer Ltd. (TSXV: ELXR.H) has announced plans to settle $6.92 million in debt through the issuance of 83.92 million common shares at $0.0825 per share. The majority of the debt settlement ($6.32 million) involves AIP Convertible Private Debt Fund L.P., a control person of the company, who will receive 76.65 million shares.
The settlement includes various secured and unsecured promissory notes, expenses, and M&A advisory fees. The company will require disinterested shareholder approval for portions of the settlement exceeding $10,000 per month to non-arm's length parties. Additionally, $573,487.98 in salary and director fees will be settled with former director Ferras Zalt through 2.42 million shares.
Elixxer Ltd. (TSXV: ELXR) provided a comprehensive corporate update addressing several key developments. The company's Failure-to-File Cease Trade Orders have been revoked as of April 17, 2025, with trading expected to resume shortly. Elixxer has appointed new leadership, including CEO Karim Mecklai and CFO Fiona Fitzmaurice, along with a refreshed board of directors.
The company has restructured its debt obligations, including extending the maturity of $8 million in secured notes plus $3.8M in accrued interest to September 30, 2025. Additionally, Elixxer secured a $1 million bridge loan facility from AIP Fund, its largest creditor and 32% shareholder. The company maintains a 19.36% stake in Freia Farmaceutici and is actively pursuing merger and acquisition opportunities while managing ongoing litigation with Tricho-Med Corporation.
Elixxer (TSXV: ELXR) has announced the revocation of cease trade orders previously issued by the Autorité des Marchés Financiers (AMF) and the Ontario Securities Commission (OSC). The cease trade orders were initially implemented on May 8, 2023, due to the company's failure to file required continuous disclosure documents.
The company has now successfully updated all its continuous disclosure filings, which are available for viewing on SEDAR+. The revocation of the Failure-to-File Cease Trade Orders was granted on April 16, 2025.
Elixxer (TSXV: ELXR) held its annual and special meeting of shareholders on March 20, 2025, with 56.44% of outstanding shares represented (6,400,078 shares). Key approvals included:
- Appointment of CAN Partners LLP as new auditors with 99.99% approval, replacing MS Partners LLP who resigned February 18, 2025
- Change of registered office from Quebec to Ontario
- Conversion of fixed stock option plan to rolling stock option plan
- Repeal of existing by-laws and enactment of new by-law no. 1
All matters presented were approved by an overwhelming majority of shareholders.
Elixxer (TSXV: ELXR) has announced the appointment of Edward Milewski as an independent director. Milewski brings 35 years of experience as a financial advisor and established ERM Consulting in 2012, providing advice to public small cap companies across Canada. He currently co-hosts 'Midas Letter Raw,' an investment show focusing on Canadian markets analysis.
Milewski holds a B. Comm from University of Windsor (1973) and obtained his CA designation in 1976. His previous board experience includes directorships at Pasofino Gold and Western Troy Capital Resources. He will serve on Elixxer's audit committee as an independent director, replacing Alex Kanayev.
Elixxer (TSXV: ELXR) has announced changes to its Board of Directors. Mark Romano, a senior executive with over 40 years of experience in technical leadership, program management, and business operations, has been appointed as an independent Director. He replaces Jeremy Green, who has resigned from his position on the Board.
FAQ
What is the current stock price of Elixxer (ELIXF)?
What is the market cap of Elixxer (ELIXF)?
